<DOC>
	<DOCNO>NCT01615627</DOCNO>
	<brief_summary>The investigator test whether hypotonic ( dilute ) remodulin solution cause less pain eutonic ( undiluted ) solution supply manufacturer .</brief_summary>
	<brief_title>Hypotonic Treprostinil Subcutaneous Infusion Control Treprostinil Related Site Pain</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>PAH standard criterion Treatment subcutaneous remodulin infusion least 3 month , stable dose 1 month Pain infusion site ( define &gt; 8 McGill Pain Questionnaire ) Known pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Subcutaneous Treprostinil</keyword>
</DOC>